AI Article Synopsis
- The study compared the effectiveness of two methotrexate (MTX) treatment regimens—weekly MTX and an 8-day MTX-folinic acid (MTX-FA) regimen—in patients with low-risk gestational trophoblastic neoplasia (GTN).
- Out of 73 patients, the MTX-FA 8-day regimen showed a higher complete response rate (83%) compared to the weekly MTX regimen (60%).
- The presence of lung metastasis was identified as a significant independent risk factor for treatment resistance, indicating that the MTX-FA 8-day regimen is generally more effective, especially for patients with higher FIGO risk scores.
Article Abstract
Aim: We aimed to compare weekly methotrexate (MTX) regimen and methotrexate-folinic acid (MTX-FA) 8-day regimen in the first line treatment of low-risk gestational trophoblastic neoplasia (GTN).
Methods: The study included 73 patients with low-risk GTN according to FIGO risk score (FIGO risk score < 7). All patients received either weekly MTX (30-50 mg/m intramuscular weekly) or MTX-FA 8-day (MTX 1 mg/kg IV on day 1, 3, 5, and 7, FA 15 mg orally on day 2, 4, 6, and 8 given 24 h after each MTX dose, every 14 days) regimens in the first-line treatment of low-risk GTN. The baseline clinicopathological characteristics and treatment outcomes were analyzed retrospectively.
Results: The median age of all patients was 29 (18-51) years, and the median FIGO risk score was 3 (1-6). Of the patients recruited, 53 received MTX-FA 8-day, and 20 had MTX weekly regimens. There was a significant difference between the two groups with respect to FIGO risk scores (3 [1-6] vs. 2 [1-5], p = 0.023, MTX-FA 8-day vs. MTX weekly, respectively). The complete response rate was significantly higher in MTX-FA 8-day group compared to MTX weekly group (83% [44/53] vs. 60% [12/20] p = 0.038). In univariate and multivariate regression analyses, only presence of lung metastasis was found to be an independent risk factor for treatment resistance (OR: 3.959, 95% CI 1.105-14.179, p = 0.035).
Conclusion: MTX-FA 8-day regimen is more effective than weekly MTX regimen in the first line treatment of low-risk GTN including patients even with higher FIGO risk scores. Treatment resistance may develop especially in patients with lung metastasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajco.13623 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dose-intensive therapy (DIT) for infantile Pompe disease: A pilot study.
Mol Genet Metab Rep
March 2025
Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Background: The current standard of care for infantile-onset Pompe disease (IOPD), a severe form of acid α-glucosidase enzyme activity deficiency is: (1) detection by newborn screening, (2) early initiation of intravenous enzyme replacement therapy (ERT) using recombinant human acid alpha-glucosidase (rhGAA), with higher doses of rhGAA increasingly used to improve clinical outcomes, and (3) immune tolerization induction (ITI) using to prevent anti-rhGAA antibody formation, with methotrexate (MTX), rituximab, and IVIG used for patients who are cross-reactive immunologic material negative (CRIM-) and monotherapy with MTX used in patients who are cross-reactive immunologic material positive (CRIM+).
Objectives/methods: A pilot study evaluates a dose-intensive therapy (DIT) using high-dose ERT (40 mg/kg/week) and more frequent exposure to ERT (i.e.
Normal tension glaucoma as initial manifestation of Takayasu arteritis- an unknown entity.
Eur J Ophthalmol
January 2025
Department of Ophthalmology, Armed Forces Medical College, Pune, Maharashtra, India.
Objective: To report an unusual manifestation of normal tension glaucoma(NTG) in a young female as presenting feature of Takayasu arteritis (TA).
Methods: We present a case of a 24-year-old woman who was initially diagnosed with NTG, with characteristic optic disc and retinal nerve fiber layer (RNFL) changes, and corresponding visual field defects. Further evaluation with CT angiography revealed that the patient had newly diagnosed TA.
Efficacy And Safety Of Low-Dose Methotrexate In Generalized And Recalcitrant Lichen Planus: A Retrospective Study At A Tertiary Care Center.
Dermatol Pract Concept
October 2024
Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, Delhi, India.
Introduction: Methotrexate (MTX) acts by suppressing multiple immune pathways involved in the pathogenesis of lichen planus (LP). Trials assessing the efficacy and relapse rates of methotrexate in LP are lacking.
Objectives: Our objective was to analyze the efficacy and safety of low-dose methotrexate in generalized and recalcitrant LP patients retrospectively and to assess the relapse rates in patients after stopping MTX therapy.
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.
An Bras Dermatol
December 2024
Department of Dermatology, Faculdade de Medicina de ABC, São Paulo, SP, Brazil.
Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit.
Objective: The authors assessed the efficacy and safety of risankizumab compared with methotrexate in adults with moderate-to-severe plaque psoriasis.
Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced -Mutant NSCLC.
JTO Clin Res Rep
December 2024
Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Article Synopsis
- A study investigated the safety and efficacy of combining regorafenib and low-dose methotrexate for patients with advanced -mutant NSCLC, as there are limited treatment options available beyond G12C inhibitors.
- The study included 18 patients, revealing a median progression-free survival of 3.7 months and a median overall survival of 10.4 months, with a 16.7% objective response rate.
- The treatment caused notable toxicity, leading to dose adjustments and discontinuations; consequently, the study did not meet its primary goal of improving progression-free survival.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!